Overcoming Cell Line Development Challenges Through CDMO Outsourcing

By Vladas Algirdas Bumelis, Prof., Dominic Chow, PhD, and Rose Rhomberg, MBA, Northway Biotech

Any company developing innovative or biosimilar biopharmaceuticals, whether small and virtual or globally established, faces numerous make-or-break decisions along each project’s journey from proposal to profitability.

In addition to market evaluation and regulatory obligations, each organization must determine a cell line able to meet its project quality and quantity needs, as well as identify a CDMO to guide its vision to commercialization. IP considerations, facility locations, production capability, and process efficiency are just a few factors affecting that decision.   

While selecting a CDMO partner for cell line development may seem like a time-consuming task, the right choice can lead to additional positive outcomes. The CDMO provides technical input based on its experience and expertise, simplifying a biopharmaceutical company’s supply chain or enabling greater operational freedom than expected.